US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cartesian Therapeutics

11.83

-0.2200-1.83%

Post-market: 11.830.00000.00%16:05 EDT

Volume:45.58K

Turnover:537.96K

Market Cap:306.48M

PE:-2.64

High:12.05

Open:11.87

Low:11.51

Close:12.05

Loading ...

Overview Company News Filings

Cartesian Therapeutics Inc - Phase 2 Sle Trial of Descartes-08 Ongoing, Data Readout Expected 2H25

THOMSON REUTERS

Intra-Cellular (ITCI) Surges 14.9%: Is This an Indication of Further Gains?

Cartesian Therapeutics announces employment inducement grants

Cartesian Therapeutics (RNAC) Has a New Rating from BTIG

Cartesian Therapeutics initiated with a Buy at BTIG

BTIG Research Initiates Coverage on Cartesian Therapeutics With Buy Rating, $42 Price Target

MT Newswires Live

Cartesian Therapeutics Files for Proposed Resale or Other Disposition by Selling Stockholders of up to 6.3 Mln Common Stock - SEC Filing

THOMSON REUTERS

Cartesian Therapeutics files $400M mixed securities shelf

Cartesian Therapeutics : Sales Agreement Prospectus Covers Offering of up to $100 Mln Common Stock That May Be Issued From Time to Time

THOMSON REUTERS

Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH), Cartesian Therapeutics (RNAC) and Terns Pharmaceuticals (TERN)

Promising Clinical Developments and Pivotal Trials Position Cartesian Therapeutics for Long-term Success

Cartesian Therapeutics Price Target Raised to $45.00/Share From $41.00 by HC Wainwright & Co.

Cartesian Therapeutics price target raised to $45 from $41 at H.C. Wainwright

Cartesian Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $45 From $41

THOMSON REUTERS

Cartesian Therapeutics Reports Promising Phase 2b Trial Results

Cartesian Therapeutics reports positive updated Phase 2b results in myasthenia

Cartesian Therapeutics Announces Positive Updated Results From Phase 2B Trial of Descartes-08 in Participants With Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial

THOMSON REUTERS

Cartesian Therapeutics Inc - Phase 2B Trial Shows 5.5-Point Reduction in Mg-Adl at Month 4

THOMSON REUTERS

Cartesian Therapeutics Inc - Phase 3 Aurora Trial to Commence in 1H2025

THOMSON REUTERS

Cartesian Therapeutics Inc -Safety Profile Consistent With Previously Reported Data and Continues to Support Outpatient Administration

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/RNAC/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RNAC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RNAC\",,,,,undefined,":{"symbol":"RNAC","market":"US","secType":"STK","nameCN":"Cartesian Therapeutics","latestPrice":11.83,"timestamp":1745611200000,"preClose":12.05,"halted":0,"volume":45578,"hourTrading":{"tag":"盘后","latestPrice":11.83,"preClose":11.83,"latestTime":"16:05 EDT","volume":578,"amount":6837.74,"timestamp":1745611508483},"delay":0,"floatShares":9302905,"shares":25907101,"eps":-4.48613,"marketStatus":"Market Closed","change":-0.22,"latestTime":"04-25 16:00:00 EDT","open":11.87,"high":12.05,"low":11.5074,"amount":537961.4995,"amplitude":0.045029,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.48613,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745827200000},"marketStatusCode":7,"adr":0,"listingDate":1466568000000,"exchange":"NASDAQ","adjPreClose":12.05,"preHourTrading":{"tag":"盘前","latestPrice":11.92,"preClose":12.05,"latestTime":"04:48 EDT","volume":3,"amount":35.440000500000004,"timestamp":1745570908669},"postHourTrading":{"tag":"盘后","latestPrice":11.83,"preClose":11.83,"latestTime":"16:05 EDT","volume":578,"amount":6837.74,"timestamp":1745611508483},"volumeRatio":0.5714737090496524,"impliedVol":1.1151,"impliedVolPercentile":0.4286},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RNAC\",,,,,undefined,":{"symbol":"RNAC","floatShares":9302905,"roa":"-6.00%","roe":"-7029.26%","lyrEps":-4.481379,"volumeRatio":0.5714737090496524,"shares":25907101,"dividePrice":0,"high":12.05,"amplitude":0.045029,"preClose":12.05,"low":11.5074,"week52Low":8.85,"pbRate":"-45.06","psRate":"7.88","week52High":41.87,"institutionHeld":0,"latestPrice":11.83,"eps":-4.48613,"divideRate":0,"volume":45578,"delay":0,"ttmEps":-4.48613,"open":11.87,"prevYearClose":17.91,"prevWeekClose":10.5,"prevMonthClose":13.18,"prevQuarterClose":13.18,"fiveDayClose":10.5,"twentyDayClose":14.36,"sixtyDayClose":19.23},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RNAC\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2503081743","title":"Cartesian Therapeutics Inc - Phase 2 Sle Trial of Descartes-08 Ongoing, Data Readout Expected 2H25","url":"https://stock-news.laohu8.com/highlight/detail?id=2503081743","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503081743?lang=en_us&edition=fundamental","pubTime":"2025-01-13 20:00","pubTimestamp":1736769601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250113:nTUANDMGZ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RNAC","BK4139"],"gpt_icon":0},{"id":"2503306324","title":"Intra-Cellular (ITCI) Surges 14.9%: Is This an Indication of Further Gains?","url":"https://stock-news.laohu8.com/highlight/detail?id=2503306324","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503306324?lang=en_us&edition=fundamental","pubTime":"2025-01-13 18:34","pubTimestamp":1736764440,"startTime":"0","endTime":"0","summary":"Intra-Cellular Therapies  shares soared 14.9% in the last trading session to close at $94.87. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 1% loss over the past four weeks.The sudden soaring of the stock price was observed after ITCI announced that it has entered into a settlement agreement with Sandozregarding the Caplyta  patent litigation.The settlement agreement resolves the patent litigation brought by Intra-Cellular on Sandoz for submitting an abbreviated new drug application to the FDA seeking marketing approval for a generic version ofCaplyta in the United States before applicable patents expire.The settlement agreement allows Sandoz to start selling generic versions of Caplyta on July 1, 2040, or earlier under specific conditions. The stock price rally has also likely been fueled by a Bloomberg article which claims that J&J is in talks to buy ITCI for $10 billion.Cartesian Therapeutics, Inc.  : F","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/intra-cellular-itci-surges-14-103400066.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0053671581.USD","LU0012050646.USD","LU0106261612.USD","LU0889565916.HKD","LU0320765992.SGD","LU0109394709.USD","BK4139","ITCI","BK4007","RNAC"],"gpt_icon":0},{"id":"2501020838","title":"Cartesian Therapeutics announces employment inducement grants","url":"https://stock-news.laohu8.com/highlight/detail?id=2501020838","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501020838?lang=en_us&edition=fundamental","pubTime":"2025-01-07 20:10","pubTimestamp":1736251827,"startTime":"0","endTime":"0","summary":"Cartesian Therapeutics (RNAC) announced the granting of inducement awards to three new employees. On January 2, 2025, the Company issued to these e...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cartesian-therapeutics-announces-employment-inducement-grants-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cartesian-therapeutics-announces-employment-inducement-grants-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNAC","BK4139"],"gpt_icon":0},{"id":"2495503939","title":"Cartesian Therapeutics (RNAC) Has a New Rating from BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2495503939","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495503939?lang=en_us&edition=fundamental","pubTime":"2024-12-31 05:15","pubTimestamp":1735593339,"startTime":"0","endTime":"0","summary":"Cartesian Therapeutics (RNAC – Research Report) received a Buy rating and a $42.00 price target from BTIG analyst Julian Harrison today. The compan...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cartesian-therapeutics-rnac-has-a-new-rating-from-btig?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cartesian-therapeutics-rnac-has-a-new-rating-from-btig?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNAC"],"gpt_icon":0},{"id":"2492411431","title":"Cartesian Therapeutics initiated with a Buy at BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2492411431","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492411431?lang=en_us&edition=fundamental","pubTime":"2024-12-20 19:50","pubTimestamp":1734695438,"startTime":"0","endTime":"0","summary":"BTIG initiated coverage of Cartesian Therapeutics  with a Buy rating and $42 price target Cartesian is pioneering the field of mRNA-based CART cell therapies for autoimmune disorders, the analyst tells investors in a research note. The firm says the company’s lead efforts are in myasthenia gravis, which has provided “important proof of concept for Descartes-08 with differentiated efficacy that looks progressive through long-term follow-up.” BTIG sees an attractive entry point for investors ahead of MG Phase 3 initiation in the first half of 2025.Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks. Cartesian Therapeutics files to sell 11.39M shares of common stock for holders. Cartesian Therapeutics files to sell 6.25M shares of common stock for holders. Cartesian Therapeutics price target raised to $45 from $41 at H.C. Wainwright","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/EWL56DETwmfBFfnXlOrIoQ--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/8948b64e92d23cb05c63afbc8ed98e4c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/EWL56DETwmfBFfnXlOrIoQ--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/8948b64e92d23cb05c63afbc8ed98e4c"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/cartesian-therapeutics-initiated-buy-btig-115038495.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cartesian-therapeutics-initiated-buy-btig-115038495.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RNAC","BK4139"],"gpt_icon":0},{"id":"2492124782","title":"BTIG Research Initiates Coverage on Cartesian Therapeutics With Buy Rating, $42 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2492124782","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492124782?lang=en_us&edition=fundamental","pubTime":"2024-12-19 20:36","pubTimestamp":1734611806,"startTime":"0","endTime":"0","summary":"Cartesian Therapeutics (RNAC) has an average rating of overweight and mean price target of $37.40, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RNAC"],"gpt_icon":0},{"id":"2491129583","title":"Cartesian Therapeutics Files for Proposed Resale or Other Disposition by Selling Stockholders of up to 6.3 Mln Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2491129583","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491129583?lang=en_us&edition=fundamental","pubTime":"2024-12-14 05:14","pubTimestamp":1734124479,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241213:nFWN3NE0T8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2491834105","title":"Cartesian Therapeutics files $400M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2491834105","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491834105?lang=en_us&edition=fundamental","pubTime":"2024-12-14 05:10","pubTimestamp":1734124218,"startTime":"0","endTime":"0","summary":"16:09 EST Cartesian Therapeutics (RNAC) files $400M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-mo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cartesian-therapeutics-files-400m-mixed-securities-shelf?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cartesian-therapeutics-files-400m-mixed-securities-shelf?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNAC","BK4139"],"gpt_icon":0},{"id":"2491921583","title":"Cartesian Therapeutics : Sales Agreement Prospectus Covers Offering of up to $100 Mln Common Stock That May Be Issued From Time to Time","url":"https://stock-news.laohu8.com/highlight/detail?id=2491921583","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491921583?lang=en_us&edition=fundamental","pubTime":"2024-12-14 05:08","pubTimestamp":1734124084,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241213:nFWN3NE0GA:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2489476451","title":"Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH), Cartesian Therapeutics (RNAC) and Terns Pharmaceuticals (TERN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2489476451","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489476451?lang=en_us&edition=fundamental","pubTime":"2024-12-06 14:11","pubTimestamp":1733465511,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on UnitedHealth (UNH – Research Report), Cartesian Ther...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-unitedhealth-unh-cartesian-therapeutics-rnac-and-terns-pharmaceuticals-tern?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-unitedhealth-unh-cartesian-therapeutics-rnac-and-terns-pharmaceuticals-tern?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1718418525.SGD","IE00BZ1G4Q59.USD","IE0004445239.USD","LU2279689827.SGD","LU1914381329.SGD","LU0079474960.USD","HCSG","LU1551013342.USD","LU0496365809.HKD","LU0417517546.SGD","IE00B19Z8X17.USD","LU0107464264.USD","SG9999001176.USD","IE00B19Z9Z06.USD","IE00BJJMRZ35.SGD","LU0976567544.SGD","BK4137","LU0557290698.USD","LU1674673428.USD","LU0029864427.USD","LU0795875169.SGD","LU2362541513.USD","LU1988902786.USD","IE00B894F039.SGD","LU0109391861.USD","LU0011850046.USD","LU1061106388.HKD","SG9999014880.SGD","BK4566","SG9999018857.SGD","IE00B7KXQ091.USD","LU1074936037.SGD","UNH","SGXZ81514606.USD","LU0912757837.SGD","LU2552382132.HKD","RNAC","SG9999018865.SGD","LU1066051498.USD","IE00BKVL7J92.USD","LU0823416689.USD","LU0672654240.SGD","LU2089283258.USD","LU2125154778.USD","LU2491050154.USD","LU0795875086.SGD","LU2089984988.USD","TERN","SGXZ57979304.SGD","LU0949170772.SGD"],"gpt_icon":0},{"id":"2489475251","title":"Promising Clinical Developments and Pivotal Trials Position Cartesian Therapeutics for Long-term Success","url":"https://stock-news.laohu8.com/highlight/detail?id=2489475251","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489475251?lang=en_us&edition=fundamental","pubTime":"2024-12-06 13:57","pubTimestamp":1733464640,"startTime":"0","endTime":"0","summary":"Analyst Thomas Smith of Leerink Partners maintained a Buy rating on Cartesian Therapeutics (RNAC – Research Report), retaining the price target of ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/promising-clinical-developments-and-pivotal-trials-position-cartesian-therapeutics-for-long-term-success?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/promising-clinical-developments-and-pivotal-trials-position-cartesian-therapeutics-for-long-term-success?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2488645091","title":"Cartesian Therapeutics Price Target Raised to $45.00/Share From $41.00 by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2488645091","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488645091?lang=en_us&edition=fundamental","pubTime":"2024-12-04 19:51","pubTimestamp":1733313060,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RNAC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 04, 2024 06:51 ET (11:51 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNAC"],"gpt_icon":0},{"id":"2488169150","title":"Cartesian Therapeutics price target raised to $45 from $41 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2488169150","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488169150?lang=en_us&edition=fundamental","pubTime":"2024-12-04 19:16","pubTimestamp":1733310972,"startTime":"0","endTime":"0","summary":"H.C. Wainwright raised the firm’s price target on Cartesian Therapeutics (RNAC) to $45 from $41 and keeps a Buy rating on the shares. The firm says...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cartesian-therapeutics-price-target-raised-to-45-from-41-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cartesian-therapeutics-price-target-raised-to-45-from-41-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNAC"],"gpt_icon":0},{"id":"2488116603","title":"Cartesian Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $45 From $41","url":"https://stock-news.laohu8.com/highlight/detail?id=2488116603","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488116603?lang=en_us&edition=fundamental","pubTime":"2024-12-04 19:10","pubTimestamp":1733310625,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241204:nAZN2QWUJO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2488913127","title":"Cartesian Therapeutics Reports Promising Phase 2b Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2488913127","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488913127?lang=en_us&edition=fundamental","pubTime":"2024-12-03 19:33","pubTimestamp":1733225617,"startTime":"0","endTime":"0","summary":"Cartesian Therapeutics ( ($RNAC) ) has provided an update. Cartesian Therapeutics announced promising results from its Phase 2b trial of Descartes-...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cartesian-therapeutics-reports-promising-phase-2b-trial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cartesian-therapeutics-reports-promising-phase-2b-trial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2488948918","title":"Cartesian Therapeutics reports positive updated Phase 2b results in myasthenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2488948918","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488948918?lang=en_us&edition=fundamental","pubTime":"2024-12-03 19:10","pubTimestamp":1733224216,"startTime":"0","endTime":"0","summary":"Cartesian Therapeutics (RNAC) announced updated efficacy and safety data from the Phase 2b trial of Descartes-08 in participants with generalized m...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cartesian-therapeutics-reports-positive-updated-phase-2b-results-in-myasthenia?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cartesian-therapeutics-reports-positive-updated-phase-2b-results-in-myasthenia?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2488990877","title":"Cartesian Therapeutics Announces Positive Updated Results From Phase 2B Trial of Descartes-08 in Participants With Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2488990877","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488990877?lang=en_us&edition=fundamental","pubTime":"2024-12-03 19:00","pubTimestamp":1733223600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241203:nTUA9YBH7N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RNAC","BK4139"],"gpt_icon":0},{"id":"2488990340","title":"Cartesian Therapeutics Inc - Phase 2B Trial Shows 5.5-Point Reduction in Mg-Adl at Month 4","url":"https://stock-news.laohu8.com/highlight/detail?id=2488990340","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488990340?lang=en_us&edition=fundamental","pubTime":"2024-12-03 19:00","pubTimestamp":1733223600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241203:nTUA9YBH7N:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2488990325","title":"Cartesian Therapeutics Inc - Phase 3 Aurora Trial to Commence in 1H2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2488990325","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488990325?lang=en_us&edition=fundamental","pubTime":"2024-12-03 19:00","pubTimestamp":1733223600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241203:nTUA9YBH7N:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RNAC","BK4139"],"gpt_icon":0},{"id":"2488324990","title":"Cartesian Therapeutics Inc -Safety Profile Consistent With Previously Reported Data and Continues to Support Outpatient Administration","url":"https://stock-news.laohu8.com/highlight/detail?id=2488324990","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488324990?lang=en_us&edition=fundamental","pubTime":"2024-12-03 19:00","pubTimestamp":1733223600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241203:nTUA9YBH7N:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RNAC","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":72,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RNAC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-13","symbol":"RNAC","fiscalQuarterEnding":"2024/12","expectedEps":-0.78,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1741838400000,"reportTimeType":"pre","actualEps":-2.4},{"market":"US","date":"2024-11-07","symbol":"RNAC","fiscalQuarterEnding":"2024/09","expectedEps":-0.78,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"pre","actualEps":-0.69},{"market":"US","date":"2024-08-08","symbol":"RNAC","fiscalQuarterEnding":"2024/06","expectedEps":-0.81,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723089600000,"reportTimeType":"pre","actualEps":0.54},{"market":"US","date":"2024-05-08","symbol":"RNAC","fiscalQuarterEnding":"2024/03","expectedEps":-0.81,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715140800000,"reportTimeType":"pre","actualEps":-1.97},{"market":"US","date":"2024-04-05","symbol":"RNAC","defaultRemindTime":1712323800000,"type":"split","dateTimestamp":1712289600000,"forFactor":30,"toFactor":1,"ratio":30}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RNAC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RNAC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.5,"hold":0.25,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":8,"updateTime":1734667200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/RNAC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"RNAC","date":"2025-04-25","current":-4.03209,"percent":0.135417,"low":-14.109752,"twenty":-2.511189,"median":-1.940728,"eighty":-1.376163,"high":-0.322359,"avg":-2.801743,"sd":3.010294,"marketCap":312180567},"quantilePoints":[{"date":"2024-02-09","current":-12.195228,"twenty":-12.293822,"median":-12.139657,"eighty":-11.530164,"marketCap":110159496},{"date":"2024-02-16","current":-13.543282,"twenty":-12.82193,"median":-12.371802,"eighty":-12.018117,"marketCap":122336468},{"date":"2024-02-23","current":-12.9069,"twenty":-13.170416,"median":-12.72226,"eighty":-12.169773,"marketCap":116588031},{"date":"2024-03-01","current":-13.113052,"twenty":-13.187625,"median":-12.9069,"eighty":-12.193077,"marketCap":118450201},{"date":"2024-03-08","current":-0.474472,"twenty":-13.096919,"median":-12.72226,"eighty":-12.104521,"marketCap":104246325},{"date":"2024-03-15","current":-0.394571,"twenty":-13.085087,"median":-12.369113,"eighty":-0.499332,"marketCap":86691095},{"date":"2024-03-22","current":-0.518772,"twenty":-13.077916,"median":-12.18985,"eighty":-0.473381,"marketCap":113979437},{"date":"2024-03-28","current":-0.486782,"twenty":-13.018401,"median":-12.095738,"eighty":-0.472836,"marketCap":106950867},{"date":"2024-04-05","current":-0.371573,"twenty":-12.924109,"median":-11.522994,"eighty":-0.462369,"marketCap":81638284},{"date":"2024-04-12","current":-1.459867,"twenty":-12.9069,"median":-1.226402,"eighty":-0.444134,"marketCap":320747357},{"date":"2024-04-19","current":-1.398365,"twenty":-12.846668,"median":-1.459867,"eighty":-0.462369,"marketCap":307234719},{"date":"2024-04-26","current":-1.691309,"twenty":-12.729072,"median":-1.487381,"eighty":-0.467868,"marketCap":371597548},{"date":"2024-05-03","current":-1.978779,"twenty":-12.63227,"median":-1.536745,"eighty":-0.471303,"marketCap":434757574},{"date":"2024-05-10","current":-1.526348,"twenty":-12.47667,"median":-1.594687,"eighty":-0.472836,"marketCap":389021718},{"date":"2024-05-17","current":-1.839158,"twenty":-12.299559,"median":-1.62026,"eighty":-0.47633,"marketCap":468748036},{"date":"2024-05-24","current":-1.777713,"twenty":-12.193077,"median":-1.671483,"eighty":-0.482182,"marketCap":453087509},{"date":"2024-05-31","current":-2.195259,"twenty":-12.18985,"median":-1.697348,"eighty":-0.489671,"marketCap":559507906},{"date":"2024-06-07","current":-2.422885,"twenty":-12.179811,"median":-1.717665,"eighty":-0.504164,"marketCap":617523039},{"date":"2024-06-14","current":-2.045138,"twenty":-12.139657,"median":-1.777713,"eighty":-0.515905,"marketCap":521246392},{"date":"2024-06-21","current":-1.598266,"twenty":-12.069386,"median":-1.728138,"eighty":-0.518199,"marketCap":407351653},{"date":"2024-06-28","current":-1.991374,"twenty":-11.947846,"median":-1.777713,"eighty":-0.520305,"marketCap":507543431},{"date":"2024-07-05","current":-1.23169,"twenty":-11.531957,"median":-1.728138,"eighty":-0.526438,"marketCap":313922113},{"date":"2024-07-12","current":-1.241477,"twenty":-11.522994,"median":-1.709478,"eighty":-0.530124,"marketCap":316416386},{"date":"2024-07-15","current":-1.240079,"twenty":-9.729226,"median":-1.703386,"eighty":-0.53751,"marketCap":316060062},{"date":"2024-08-02","current":-1.081399,"twenty":-7.935458,"median":-1.699966,"eighty":-0.544895,"marketCap":275617201},{"date":"2024-08-09","current":-1.198323,"twenty":-2.548847,"median":-1.676743,"eighty":-0.772791,"marketCap":275192581},{"date":"2024-08-16","current":-1.345437,"twenty":-2.529995,"median":-1.625846,"eighty":-1.101689,"marketCap":308976908},{"date":"2024-08-23","current":-1.244878,"twenty":-2.507232,"median":-1.598266,"eighty":-1.148418,"marketCap":285883824},{"date":"2024-08-30","current":-1.388267,"twenty":-2.46827,"median":-1.531547,"eighty":-1.172903,"marketCap":318812851},{"date":"2024-09-06","current":-1.307262,"twenty":-2.424002,"median":-1.519153,"eighty":-1.173531,"marketCap":300210089},{"date":"2024-09-13","current":-1.496275,"twenty":-2.390626,"median":-1.497092,"eighty":-1.177113,"marketCap":343616533},{"date":"2024-09-20","current":-1.540036,"twenty":-2.248325,"median":-1.497406,"eighty":-1.182548,"marketCap":353666301},{"date":"2024-09-27","current":-1.616387,"twenty":-2.173184,"median":-1.49772,"eighty":-1.183457,"marketCap":371199939},{"date":"2024-10-04","current":-2.374287,"twenty":-2.173184,"median":-1.519153,"eighty":-1.187433,"marketCap":545250240},{"date":"2024-10-11","current":-2.176603,"twenty":-2.352646,"median":-1.530726,"eighty":-1.193387,"marketCap":499852543},{"date":"2024-10-18","current":-2.257757,"twenty":-2.310612,"median":-1.544226,"eighty":-1.200277,"marketCap":518489492},{"date":"2024-10-25","current":-2.299664,"twenty":-2.339564,"median":-1.569114,"eighty":-1.208188,"marketCap":528113202},{"date":"2024-10-31","current":-2.199769,"twenty":-2.325678,"median":-1.616387,"eighty":-1.208566,"marketCap":505172538},{"date":"2024-11-08","current":-2.028231,"twenty":-2.320475,"median":-1.625846,"eighty":-1.217877,"marketCap":496569789},{"date":"2024-11-15","current":-1.766791,"twenty":-2.31186,"median":-1.676743,"eighty":-1.221601,"marketCap":432561563},{"date":"2024-11-22","current":-1.725268,"twenty":-2.307988,"median":-1.693927,"eighty":-1.221601,"marketCap":422395604},{"date":"2024-11-29","current":-1.954681,"twenty":-2.306323,"median":-1.709478,"eighty":-1.229672,"marketCap":478562529},{"date":"2024-12-06","current":-2.388593,"twenty":-2.306323,"median":-1.725268,"eighty":-1.23169,"marketCap":584796802},{"date":"2024-12-13","current":-2.088591,"twenty":-2.321516,"median":-1.757967,"eighty":-1.238401,"marketCap":511347747},{"date":"2024-12-20","current":-2.024787,"twenty":-2.313583,"median":-1.76875,"eighty":-1.241197,"marketCap":495726646},{"date":"2024-12-27","current":-2.088883,"twenty":-2.309537,"median":-1.777713,"eighty":-1.243092,"marketCap":511419083},{"date":"2025-01-03","current":-1.778913,"twenty":-2.307156,"median":-1.777862,"eighty":-1.244452,"marketCap":435529430},{"date":"2025-01-10","current":-1.777862,"twenty":-2.305849,"median":-1.777862,"eighty":-1.244878,"marketCap":435272177},{"date":"2025-01-17","current":-1.989062,"twenty":-2.304427,"median":-1.779554,"eighty":-1.246554,"marketCap":486980042},{"date":"2025-01-24","current":-2.040548,"twenty":-2.299664,"median":-1.784789,"eighty":-1.253258,"marketCap":499585442},{"date":"2025-01-31","current":-2.036345,"twenty":-2.283748,"median":-1.80308,"eighty":-1.272811,"marketCap":498556430},{"date":"2025-02-07","current":-1.976453,"twenty":-2.276485,"median":-1.8278,"eighty":-1.28026,"marketCap":483893005},{"date":"2025-02-14","current":-1.999569,"twenty":-2.273364,"median":-1.845442,"eighty":-1.299813,"marketCap":489552573},{"date":"2025-02-21","current":-2.060513,"twenty":-2.263946,"median":-1.859179,"eighty":-1.303538,"marketCap":504473250},{"date":"2025-02-28","current":-1.892393,"twenty":-2.258524,"median":-1.87682,"eighty":-1.306703,"marketCap":463312761},{"date":"2025-03-07","current":-1.875581,"twenty":-2.211367,"median":-1.875581,"eighty":-1.307262,"marketCap":459196712},{"date":"2025-03-14","current":-5.557927,"twenty":-2.211367,"median":-1.881886,"eighty":-1.317995,"marketCap":430316947},{"date":"2025-03-21","current":-5.33039,"twenty":-2.277938,"median":-1.88594,"eighty":-1.323353,"marketCap":412700118},{"date":"2025-03-28","current":-4.805047,"twenty":-2.306323,"median":-1.893969,"eighty":-1.325512,"marketCap":372025970},{"date":"2025-04-04","current":-4.129128,"twenty":-2.32984,"median":-1.905491,"eighty":-1.337057,"marketCap":319693626},{"date":"2025-04-11","current":-3.466594,"twenty":-2.375387,"median":-1.926854,"eighty":-1.34432,"marketCap":268397566},{"date":"2025-04-17","current":-3.536863,"twenty":-2.423443,"median":-1.931271,"eighty":-1.357169,"marketCap":273838057},{"date":"2025-04-25","current":-4.03209,"twenty":-2.511189,"median":-1.940728,"eighty":-1.376163,"marketCap":312180567}],"updateTime":1745801212664}}}